Can Alnylam’s AMVUTTRA become a first-line treatment force in ATTR-CM?
ATTR-CM treatment is shifting earlier. Alnylam must now prove AMVUTTRA can win clinician trust beyond trial subgroups.
Novo Nordisk–Prothena coramitug program reaches key Phase 3 milestone in ATTR cardiomyopathy
Prothena earns a $50M milestone as Novo Nordisk advances coramitug in Phase 3 for ATTR cardiomyopathy. Discover what this means for amyloid therapies.